Aberdeen Group
HRMY icon

Aberdeen Group’s Harmony Biosciences HRMY Stock Holding History

Aberdeen Group’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-295,811
Closed -$8.92M – 940
2024
Q2 		$8.92M Sell
295,811
-212,438
-42% -$6.39M 0.02% 531
2024
Q1 		$17.1M Sell
508,249
-24,940
-5% -$800K 0.03% 436
2023
Q4 		$17.2M Sell
533,189
-48,455
-8% -$1.35M 0.04% 426
2023
Q3 		$19.1M Sell
581,644
-62,604
-10% -$2.17M 0.05% 329
2023
Q2 		$22.7M Buy
644,248
+14,588
+2% +$504K 0.05% 319
2023
Q1 		$20.6M Sell
629,660
-61,074
-9% -$2.78M 0.05% 343
2022
Q4 		$38.1M Buy
+690,734
New +$38M 0.1% 213

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aberdeen Group's HRMY Position: Q3 2024 in Review

Aberdeen Group sold out of Harmony Biosciences (HRMY) in Q3 2024, closing a stake of 295,811 shares — an estimated $8.92M sold.

Aberdeen Group first reported a position in HRMY in Q4 2022 and held it in 7 quarters. The position peaked at $38.1M in Q4 2022. 233 funds tracked by Wall St. Rank hold HRMY as of Q3 2024.

  • Aberdeen Group reported no remaining Harmony Biosciences position as of Q3 2024 after selling out during the quarter.
  • Aberdeen Group sold 295,811 Harmony Biosciences shares in Q3 2024, an estimated $8.92M.
  • Aberdeen Group first reported a position in Harmony Biosciences in Q4 2022 and held it in 7 quarters.
  • Aberdeen Group's Harmony Biosciences position peaked at $38.1M in Q4 2022.
  • 233 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2024.

Based on Aberdeen Group's 13F filing for Q3 2024, filed 25 Oct 2024.